Published in Women's Health Weekly, January 8th, 2004
The data was presented at the 26th Annual San Antonio Breast Cancer Symposium held December 3-6, 2003, in San Antonio, Texas.
Data from the study concluded that TamoGel has a local impact on tumor proliferation with much lower systemic exposure than tamoxifen, and that TamoGel can be tested in future prospective trials of chemoprevention or ductal carcinoma in situ (DCIS) adjuvant therapy.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly